dc.contributor.author | Pérez-García, Felipe | |
dc.contributor.author | Soria, Susana | |
dc.contributor.author | Jorge-Monjas, Pablo | |
dc.contributor.author | Gómez-Sánchez, Esther | |
dc.contributor.author | Heredia-Rodríguez, María | |
dc.contributor.author | Gómez-Pesquera, Estefanía | |
dc.contributor.author | Martínez-Paz, Pedro | |
dc.contributor.author | Tamayo, Eduardo | |
dc.contributor.author | Resino, Salvador | |
dc.contributor.author | Fernandez-Rodriguez, Amanda | |
dc.contributor.author | Jimenez-Sousa, Maria Angeles | |
dc.date.accessioned | 2020-08-10T08:33:16Z | |
dc.date.available | 2020-08-10T08:33:16Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | Front Med (Lausanne) . 2020 May 14;7:186. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/10878 | |
dc.description.abstract | Interferon lambda 3 (IFNL3, previously called IL-28B) is a cytokine with effects against viral and bacterial pathogens. We aimed to analyze the IFNL3 rs12980275 SNP in patients who underwent major surgery, in order to establish its relationship with susceptibility to septic shock and septic shock-related death in these patients. We performed a case-control study on 376 patients to establish the association between IFNL3 rs12980275 SNP and the susceptibility to develop septic shock. Besides, we performed a longitudinal study among 172 septic shock patients using survival analysis with one censoring point of 28-days mortality. The IFNL3 rs12980275 polymorphism was genotyped by Agena Bioscience's MassARRAY platform. IFNL3 rs12980275 polymorphism was not associated with higher susceptibility to infection and septic shock development. Regarding survival analysis, the Kaplan-Meier analysis showed that patients with IFNL3 rs12980275 AA genotype had higher survival than patients with GG genotype (p = 0.003). The Cox regression analysis adjusted by the most relevant clinical and epidemiological characteristics showed that the GG genotype (recessive model) and the presence of the G allele (additive model) were associated with higher risk of death [adjusted hazard ratio (aHR) = 2.15, p = 0.034; aHR = 1.50, p = 0.030, respectively]. In conclusion, IFNL3 rs12980275 polymorphism was associated with septic shock-related death in patients who underwent major surgery. The A allele was linked to protection, and the G allele was associated with an increased risk of death. This is a first preliminary study that suggests for the first time a role of IFNL3 polymorphisms in the prognosis of septic shock. | es_ES |
dc.description.sponsorship | This work has been supported by grants given by Instituto de Salud Carlos III (grant numbers PI15/01451 to ET), Gerencia de Salud, Consejería de Sanidad, Junta de Castilla y Leon (grant number GRS 463/A/10 and 773/A/13 to ET), and PFIZER (grant number CT25-ESP01-01 to SR). MJ-S and AF-R are supported by Instituto de Salud Carlos III (grant numbers CP17CIII/00007 and CP14CIII/00010, respectively). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Frontiers Media | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject.mesh | IFNL3 | es_ES |
dc.subject.mesh | SNP | es_ES |
dc.subject.mesh | Major surgery | es_ES |
dc.subject.mesh | rs12980275 | es_ES |
dc.subject.mesh | Sepsis | es_ES |
dc.subject.mesh | septic shock | es_ES |
dc.subject.mesh | Survival | es_ES |
dc.title | IFNL3 rs12980275 Polymorphism Predicts Septic Shock-Related Death in Patients Undergoing Major Surgery: A Retrospective Study | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 32478085 | es_ES |
dc.format.volume | 7 | es_ES |
dc.identifier.doi | 10.3389/fmed.2020.00186 | es_ES |
dc.contributor.funder | Pfizer | |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.contributor.funder | Junta de Castilla y León (España) | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 2296-858X | es_ES |
dc.relation.publisherversion | https://doi.org/10.3389/fmed.2020.00186 | es_ES |
dc.identifier.journal | Frontiers in Medicine | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/PI15/01451 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/463/A/10 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/773/A/13 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/CT25-ESP01-01 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/CP17CIII/00007 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/CP14CIII/00010 | es_ES |
dc.rights.accessRights | open access | es_ES |